Introduction: Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not amenable to surgery and radiation therapy. Common adverse events of vismodegib, probably mechanism related, include alopecia (58%) as a reversible side effect. Case Presentation: We report 2 cases of patients receiving vismodegib for the treatment of locally advanced BCCs that developed alopecia during treatment and describe clinical, dermoscopic, and reflectance confocal microscopy (RCM) features of this adverse event. Conclusion: Alopecia is one of the most distressing adverse events leading to vismodegib discontinuations. To our knowledge, these are the fir...
ABSTRACT Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity...
Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell ...
Background: Chemotherapy-induced alopecia (CIA) affects 65% of patients receiving chemotherapy regim...
Introduction: Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the...
Locally advanced basal cell carcinoma had always represented a form of skin cancer which had been di...
Although surgery represents the treatment of choice for the majority of basal cell carcinomas, diffe...
Background Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administrat...
BACKGROUND The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with ad...
BackgroundVismodegib is approved for treatment of advanced basal cell carcinoma.ObjectiveWe sought t...
Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed...
Background: Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administra...
BackgroundVismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administrati...
Non-melanoma skin cancer (NMSC) is the most common type of human tumor, with an estimated five milli...
Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not ...
Basal cell carcinoma (BCC) is the most common skin cancer in humans. Pigmented basal cell carcinoma ...
ABSTRACT Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity...
Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell ...
Background: Chemotherapy-induced alopecia (CIA) affects 65% of patients receiving chemotherapy regim...
Introduction: Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the...
Locally advanced basal cell carcinoma had always represented a form of skin cancer which had been di...
Although surgery represents the treatment of choice for the majority of basal cell carcinomas, diffe...
Background Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administrat...
BACKGROUND The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with ad...
BackgroundVismodegib is approved for treatment of advanced basal cell carcinoma.ObjectiveWe sought t...
Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed...
Background: Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administra...
BackgroundVismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administrati...
Non-melanoma skin cancer (NMSC) is the most common type of human tumor, with an estimated five milli...
Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not ...
Basal cell carcinoma (BCC) is the most common skin cancer in humans. Pigmented basal cell carcinoma ...
ABSTRACT Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity...
Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell ...
Background: Chemotherapy-induced alopecia (CIA) affects 65% of patients receiving chemotherapy regim...